Accuray (NASDAQ:ARAY) will announce its earnings results after the market closes on Tuesday, January 23rd. Analysts expect the company to announce earnings of ($0.08) per share for the quarter.

Accuray (NASDAQ:ARAY) last released its quarterly earnings data on Tuesday, October 24th. The medical equipment provider reported ($0.07) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.09) by $0.02. The firm had revenue of $91.00 million during the quarter, compared to analysts’ expectations of $88.26 million. Accuray had a negative return on equity of 55.18% and a negative net margin of 7.49%. Accuray’s revenue was up 5.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.12) earnings per share. On average, analysts expect Accuray to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Accuray (ARAY) opened at $5.05 on Tuesday. The stock has a market capitalization of $418.77, a price-to-earnings ratio of -14.43 and a beta of 1.29. The company has a debt-to-equity ratio of 2.44, a current ratio of 1.48 and a quick ratio of 0.92. Accuray has a 52-week low of $3.60 and a 52-week high of $6.00.

Several research analysts have issued reports on ARAY shares. Zacks Investment Research upgraded Accuray from a “hold” rating to a “buy” rating and set a $4.75 price objective for the company in a research report on Tuesday, October 24th. Lake Street Capital started coverage on Accuray in a research report on Thursday, November 30th. They issued a “buy” rating and a $10.00 price objective for the company. Cowen reiterated a “buy” rating and issued a $9.00 price objective on shares of Accuray in a research report on Friday, October 27th. BidaskClub cut Accuray from a “buy” rating to a “hold” rating in a research report on Tuesday, December 12th. Finally, JPMorgan Chase & Co. cut Accuray from a “neutral” rating to an “underweight” rating and set a $6.00 price objective for the company. in a research report on Wednesday, December 13th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $6.82.

In other Accuray news, CEO Joshua Levine sold 17,093 shares of the company’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $4.86, for a total value of $83,071.98. Following the sale, the chief executive officer now owns 1,435,428 shares of the company’s stock, valued at $6,976,180.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Kevin Waters sold 7,154 shares of the company’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $5.06, for a total value of $36,199.24. Following the completion of the sale, the chief financial officer now directly owns 335,087 shares in the company, valued at approximately $1,695,540.22. The disclosure for this sale can be found here. Insiders sold 26,413 shares of company stock worth $129,798 in the last three months. 3.90% of the stock is owned by corporate insiders.

COPYRIGHT VIOLATION NOTICE: “Accuray (ARAY) to Release Quarterly Earnings on Tuesday” was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The legal version of this story can be read at https://www.americanbankingnews.com/2018/01/16/accuray-aray-to-release-quarterly-earnings-on-tuesday.html.

About Accuray

Accuray Incorporated is a radiation oncology company. The Company develops, manufactures and markets medical devices used in radiation therapy for the treatment of cancer patients. Its products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT) and adaptive radiation therapy.

Earnings History for Accuray (NASDAQ:ARAY)

Receive News & Ratings for Accuray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray and related companies with MarketBeat.com's FREE daily email newsletter.